The guidance cut is the most significant signal, the lost customer revenue is not being replaced quickly enough. Traders should watch the upcoming 10-Q filing for segment-level detail and any updates on new biopharma customer wins. Given the prolonged revenue decline, UTMD may need to pivot to cost-cutting or M&A to stabilize earnings. The stock's 23% YTD gain (to $68.98) may face headwinds if the market reprices for lower growth.
How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 23 $64.18entry
- T+1 · 4mo ago +4.61%α +4.51% · $67.14
- T+5 · 4mo ago +8.40%α +7.92% · $69.57
- T+20 · 3mo ago +11.28%α +7.97% · $71.42
- T+60 · 5w ago +16.73%α +12.18% · $74.92
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
UTMD reported Q2 2026 revenue of $8.5M, down 14.3% YoY, and EPS of $0.844, down 10.1% YoY, reflecting the continued loss of its two largest customers (PendoTECH and China distributor). Management lowered full-year 2026 revenue guidance to a 10-13% decline from prior expectations of flat sales, as new product sales to biopharma customers have been slower than anticipated. The balance sheet remains debt-free with $87.5M cash, but the top-line trajectory and guidance cut signal ongoing headwinds.
Key Financial Metrics
Key Facts
- Q2 2026 revenue fell 14.3% to $8.53M vs $9.95M in Q2 2025; EPS declined 10.1% to $0.844 from $0.939
- Full-year 2026 revenue guidance lowered to a 10-13% decline (from prior expectation of flat vs 2025) due to slower-than-expected new product sales
- Loss of two former largest customers (PendoTECH OEM and China distributor) accounted for 75% of the Q2 revenue decline
- Litigation expense guidance raised: 2026 now expected to be less than $1.6M (vs $1.355M in 2025), reversing prior expectation of a decline
- Balance sheet remains strong with $87.5M cash and no debt; share repurchases minimal at $0.2M in 1H 2026 vs $6.7M in 1H 2025
Financial Impact
Revenue decline of $1.42M in Q2 and $2.41M in 1H; EPS decline of 10.1% in Q2. Full-year guidance implies $3-4M revenue shortfall vs prior plan.
Risk Factors
- Continued revenue concentration risk, two former customers accounted for $2.9M in 2025 sales with no replacement yet
- Litigation expenses could exceed the revised $1.6M estimate if cases go to trial
- Operating leverage works in reverse, fixed manufacturing overhead and G&A (health plan, litigation) compress margins on lower sales
- New product sales to biopharma OEM customers are developing slower than expected, delaying the revenue recovery
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001096906-26-001112 |
| Document: utmd-20260723_8k.htm | 0001096906-26-001112 |
| Document: 0001096906-26-001112-index-headers.html | 0001096906-26-001112 |
| Document: 0001096906-26-001112-index.html | 0001096906-26-001112 |
| Document: 0001096906-26-001112.txt | 0001096906-26-001112 |
| 8-K Data (Synthetic) | 0001096906-26-001112 |
Track record
11 reports on UTMD
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 3, 202613d ago 8-K Neutral 2/10 Entry $70.02 Now $72.36 +3.34% settles Dec 2
- Oct 29, 202618d ago Insider Buy Neutral 3/10 Entry $68.08 Now $72.36 +6.29% settles Nov 30
- Oct 29, 202618d ago SC TO-I/A Neutral 4/10 Entry $66.80 Now $72.36 +8.32% settles Nov 27
- Oct 22, 202625d ago 8-K Mixed 5/10 Entry $75.06 Now $72.36 −3.60% settles Nov 19
- Oct 5, 20266w ago SC TO-I/A Neutral 3/10 Entry $73.31 to $68.08 Now $72.36 −1.30% ▼ −7.14% −4.67% vs SPY
- Sep 25, 20267w ago SC TO-C Neutral 2/10 Entry $74.18 to $74.23 Now $72.36 −2.45% ▲ +0.07% +1.54% vs SPY
- Sep 24, 20267w ago SC TO-C Mixed 6/10 Entry $74.18 to $74.23 Now $72.36 −2.45% ▲ +0.07% +1.54% vs SPY
- Sep 23, 20267w ago SC TO-I Mixed 5/10 Entry $74.75 to $75.06 Now $72.36 −3.20% ▲ +0.41% +0.83% vs SPY
- Aug 31, 202611w ago 8-K Bullish 5/10 Entry $71.13 to $74.95 Now $72.36 +1.73% ▲ +5.37% +5.56% vs SPY
- Jul 23, 202616w ago 8-K Bearish 7/10 Viewing Entry $64.18 to $71.42 Now $72.36 −12.75% ▼ −11.28% −7.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers